Living with Women’s Care Approximately 93% of cervical cancer cases are preventable! Primary screening for cervical cancer HPV DNA test Only a few years ago, cytological screening (smear) was the only diagnostic approach for the prevention of cervical cancer. The discovery of the human papillomavirus HPV as a cause of cervical cancer has led to important technological advances, including the development of molecular genetic tests for HPV to identify women who are carriers and/or exhibit HPV-associated oncogenic activity. Today, the HPV DNA test is used alongside the pap smear (PAP test) to screen for cervical cancer. The HPV DNA test is aimed at detecting HPV types that are associated with a high risk of developing cervical cancer. The detection of the virus is possible at a very early stage of the onset of infection and long before the establishment of HPV initiated atypical cytological changes in the smear. This makes the HPV DNA test a unique early prognostic marker for cervical cancer. At the same time, it helps determine the therapeutic course. Anyone can be a carrier of HPV without having symptoms of it. The process from HPV infection to the onset of cancer incidence is slow. This makes the initiating infections and lesions preceding the disease suitable for regular prophylaxis in order to prevent the development of cervical cancer. With Genika’s diagnostic solutions, 93% of cervical cancer is preventable. Combined screening with ThinPrep® PAP test + HPV test provides the best possible annual prevention against cervical cancer. Cervical cancer is the second most common cancer in the world among women between the ages of 20 and 55. Its causative agent is the human papillomavirus (HPV). Cervical cancer is the end stage of untreated HPV infection, which is characterized by the persistent presence of HPV and is detected by repeated DNA testing of cervical samples.